Pharmaceuticals, Biotechnology and Life Sciences
U.S. FDA Approves YUVEZZI™ as the only dual-agent, once daily presbyopia-correcting eye drop LONDON & SEATTLE–(BUSINESS WIRE)–Tenpoint Therapeutics, Ltd., a…
YUVEZZI (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% is the only dual-agent presbyopia-correcting eye drop intentionally designed to deliver durability,…
Activity Report for Quarter Ended December 31, 2025 (Appendix 4C)NEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO;…
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to…
CAMBRIDGE, Mass. & MONTREAL–(BUSINESS WIRE)–Repare Therapeutics Inc. (“Repare” or the “Company”) announced today the completion of the previously announced acquisition…
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–$QNCX #biotech–Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of…
DUBLIN–(BUSINESS WIRE)–The “Orphan Drugs Service Market Report 2025” has been added to ResearchAndMarkets.com’s offering. The global orphan drugs service market…
This Important Milestone Represents the Initiation of the Final Development Phase Before Commercial Approval LOWELL, Mass.–(BUSINESS WIRE)–#BoneRepair–RevBio, Inc., announced that…
PRINCETON, N.J.–(BUSINESS WIRE)–Taiho Oncology, Inc., a company developing and commercializing novel treatments for hematologic malignancies and solid tumors, announced today…
TURIN, Italy–(BUSINESS WIRE)–Reply [EXM, STAR: REY] today announced the start of a collaboration with the Department of Pathophysiology and Transplantation…